SP-selectin is a useful biomarker for cardiovascular risk: findings from an elderly primary healthcare population. Issue 1 (March 2015)

• Record Type: Journal Article
• Authors: Alehagen, Urban; Lindahl, Tomas L.
• Is Part Of: Cardiovascular endocrinology. Volume 4:Issue 1(2015:Mar.)
• Publication Date: 2015-03
• Subjects: biomarker -- cardiovascular risk -- sex -- sP-selectin; Cardiovascular system -- Diseases -- Periodicals; Endocrine glands -- Diseases -- Periodicals; Endocrinology -- Periodicals; Cardiovascular Diseases -- Periodicals; Endocrine System Diseases -- Periodicals; Cardiovascular system -- Diseases; Endocrine glands -- Diseases; Endocrinology; Periodicals; 616.1
• DOI: 10.1097/XCE.0000000000000042
• Languages: English
• ISSNs: 2162-688X

Abstract

Abstract : Objectives: sP-selectin is a marker for atherosclerosis and inflammation. It provides prognostic information on cardiovascular events, as reported in the literature. The aim of the present study was to evaluate sP-selectin as a biomarker for cardiovascular mortality in an elderly primary healthcare population, with a focus on possible sex differences. Methods: The study included 437 elderly healthy participants from an epidemiological project living in a rural municipality. Clinical examination, echocardiography, and biomarker measurements were performed. All participants were followed for 5.2 years and all mortality was registered. Results: sP-selectin was shown to provide significant prognostic information also when including NT-proBNP in a multivariate setting over 5 years with a hazard ratio of 3.12 (95% confidence interval 1.57–6.18) for cardiovascular mortality and a hazard ratio of 2.46 (95% confidence interval 1.39–4.34) for all-cause mortality. The addition of D-dimer to the model did not weaken the results. The sex-specific analyses showed that sP-selectin could be used in both sexes with equally good results; however, there are signs indicating possibly a worse prognosis for women with high-serum levels of sP-selectin. Conclusion: sP-selectin is a prognostic biomarker for mortality in an elderly primary healthcare population. Compared with NT-proBNP, sP-selectin is at least as effective. We therefore suggest sP-selectin as an additional biomarker to be used in assessing the elderly to identify those at risk of cardiovascular events. The results presented should be considered hypothesis-generating, and warrant more research.